Skip to main content
Three researcher in a lab)

Investigator-Initiated Studies

Our Commitment

CSL Behring is committed to saving lives and improving the quality of life for people with rare and serious diseases worldwide. This commitment is reflected in the support for Investigator-Initiated Studies (IIS) that advance medical and scientific knowledge of CSL Behring products and the diseases they are designed to treat. CSL Behring also supports innovative clinical and basic science studies that address important medical and scientific questions related to our therapeutic areas of focus.

Areas of Focus

  • Immunodeficiency
  • Haemophilia Disorders
  • Immune-mediated Neuromuscular Disorders
  • Acquired & Oral Anticoagulant-Associated Bleeding
  • Hereditary Angioedema (HAE)

The link below is for US physicians, researchers and institutions interested in conducting their own research. For those outside the US, contact your local CSL Behring Medical Affairs representative. We receive many requests for support and carefully evaluate each one. Priority is given to proposals that align with our interests.

Disclaimer: All materials submitted as IIS application must be non-confidential. By submitting an IIS application, you acknowledge that CSL Behring is under no obligation of confidentiality with respect to materials submitted.

Research Priorities and Eligibility

Frequently Asked Questions